Arbutus Biopharma (ABUS) EBIT (2013 - 2026)

Arbutus Biopharma has disclosed EBIT across 14 years of filings, most recently posting $168.9 million for Q1 2026.

• EBIT for Q1 2026 came in at $168.9 million, up 757.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $156.4 million (up 289.28% YoY), and the FY2025 annual result was -$38.2 million, up 50.0% from the prior year.
• EBIT came in at $168.9 million for Q1 2026 at Arbutus Biopharma, up from -$5.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $168.9 million in Q1 2026 to a low of -$25.7 million in Q1 2025.
• The 5-year median for EBIT is -$17.8 million (2022), against an average of -$5.2 million.
• Across the five-year window, EBIT tumbled 58.68% in 2023 and soared 757.26% in 2026, its largest moves.
• Arbutus Biopharma's EBIT stood at -$22.6 million in 2022, then climbed by 8.04% to -$20.7 million in 2023, then surged by 32.84% to -$13.9 million in 2024, then surged by 62.03% to -$5.3 million in 2025, then jumped by 3292.97% to $168.9 million in 2026.
• The last three EBIT figures came in at $168.9 million (Q1 2026), -$5.3 million (Q4 2025), and -$8.7 million (Q3 2025), per Business Quant data.